8-K: Assembly Bio's ABI-5366 Exceeds Genital Herpes Trial Targets

Assembly Biosciences announced positive interim Phase 1b results for ABI-5366, an investigational long-acting herpes simplex virus inhibitor, showing significant reductions in viral shedding and genital lesions.

Summary

• Interim results from the Phase 1b clinical study of ABI-5366, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor, were announced for recurrent genital herpes.
• Highly potent antiviral activity was observed with a 94% reduction in HSV type 2 (HSV-2) shedding rate compared to placebo (p<0.01) over a 29-day evaluation period in the cohort evaluating a 350 mg weekly dose.
• This 94% reduction in HSV-2 shedding rate exceeds the company's target for the study of an 80%-85% reduction.
• A 94% reduction in genital lesion rate compared to placebo (p<0.01) was observed with the 350 mg weekly dose.
• The rate of samples with high viral load (i.e., >10^4 copies/mL HSV DNA) was reduced by 98% compared to placebo (p<0.05) in the 350 mg weekly dose cohort.
• ABI-5366 was observed to be well-tolerated at oral doses up to 350 mg weekly in participants seropositive for HSV-2 with recurrent genital herpes.
• The observed pharmacokinetic (PK) profile continues to support once-weekly dosing and the potential for once-monthly oral dosing regimens.
• The company expects to move directly into Phase 2 clinical study preparation in parallel with the completion of this Phase 1b study.
• The in-life portions of chronic toxicology studies of ABI-5366 are complete and are expected to support longer-term dosing in Phase 2.

Sentiment

Score: 9

Explanation: The results are overwhelmingly positive, exceeding efficacy targets and demonstrating a favorable safety profile, supporting progression to Phase 2. This represents a significant step forward for a drug targeting a condition with limited new treatments in decades.

Positives

• 94% reduction in HSV-2 shedding rate, significantly exceeding the company's target of 80%-85%.
• 94% reduction in genital lesion rate observed with the 350 mg weekly dose.
• 98% reduction in high viral load shedding rate, a potential surrogate for HSV-2 transmission.
• All key efficacy endpoints (HSV-2 shedding, genital lesion rate, high viral load shedding) showed statistically significant reductions compared to placebo (p<0.01 or p<0.05).
• ABI-5366 was well-tolerated at oral doses up to 350 mg weekly, with the majority of treatment-emergent adverse events (TEAEs) being Grade 1 or 2.
• The pharmacokinetic profile supports convenient once-weekly and potentially once-monthly oral dosing regimens.
• Chronic toxicology studies are complete, supporting longer-term dosing in future Phase 2 studies.
• The company plans to move directly into Phase 2 clinical study preparation, indicating strong confidence in the data.

Negatives

• Five participants discontinued treatment in the 150/30 mg and 350 mg cohorts (one due to an adverse event, three withdrew consent, one withdrew for recurrence of genital herpes).
• One Grade 3 adverse event (hypertriglyceridemia) was reported, which led to study discontinuation but was not considered treatment-related.
• Three participants had treatment-emergent Grade 3 laboratory abnormalities, all considered unrelated to assigned treatment.

Risks

• Ability to maintain financial resources and secure additional funding necessary to continue research activities, clinical studies, and other business operations.
• Ability to realize the potential benefits of the collaboration with Gilead Sciences, Inc., including all financial aspects and equity investments.
• Ability to initiate and complete clinical studies involving therapeutic product candidates, including those contemplated by the Gilead collaboration, in the currently anticipated timeframes or at all.
• Safety and efficacy data from clinical or nonclinical studies may not warrant further development of product candidates.
• Clinical and nonclinical data may not differentiate product candidates from other companies' candidates.
• Potential effects of changes in government regulation, including as a result of the change in U.S. administration in 2025.
• Results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies.

Future Outlook

The company expects to move directly into Phase 2 clinical study preparation for ABI-5366, with initiation anticipated in mid-2026. They also plan to share interim data from the ABI-1179 study and the ongoing monthly dosing cohort of ABI-5366 in the fall of 2025. Chronic toxicology studies are complete and expected to support longer-term dosing in Phase 2.

Management Comments

• "We are thrilled to see these interim data for ABI-5366 far exceeding the targets we had set in this study for antiviral activity and clinical outcomes in participants with recurrent genital herpes." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "These results underscore our conviction in the potential for ABI-5366 to reduce outbreaks and improve quality of life for those affected by the severe impacts of recurrent genital herpes." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "We will now work quickly to move ABI-5366 into longer-duration Phase 2 clinical studies, which we expect to initiate in mid-2026, and look forward to its continued progress." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.

Industry Context

Genital herpes is a chronic viral infection caused by HSV, affecting over four million people in the United States and major European countries, with most HSV-2 infected individuals experiencing frequent recurrences. The current standard of care, nucleoside analogs, is only partially effective in preventing recurrences and reducing transmission. Notably, no new drugs have been approved in the United States or Europe to treat genital herpes for more than 25 years, highlighting a significant unmet medical need. Helicase-primase inhibition, the mechanism of ABI-5366, is a clinically validated approach that has shown potential for superior efficacy to current standard of care.

Comparison to Industry Standards

• The current standard of care for recurrent genital herpes, nucleoside analogs, is only partially effective in preventing recurrences and reducing viral transmission.
• No new drugs have been approved in the United States or Europe to treat genital herpes for over 25 years, indicating a substantial lack of innovation and unmet patient need in the market.
• The 94% reduction in HSV-2 shedding rate observed with ABI-5366 significantly exceeds Assembly Bio's own target of 80%-85% reduction, suggesting a potentially superior efficacy profile compared to existing treatments.
• The 94% reduction in genital lesion rate and 98% reduction in high viral load shedding rate demonstrate a comprehensive and highly effective antiviral response, potentially offering a significant improvement over current options.
• The observed pharmacokinetic profile supporting once-weekly and potentially once-monthly dosing for ABI-5366 offers a significant convenience advantage over daily regimens of current standard of care, which could improve patient adherence and quality of life.

Related Party Transactions

• Under a collaboration agreement with Gilead Sciences, Inc., Gilead has the right to opt in to an exclusive license for further development and commercialization of the helicase-primase inhibitor program after reviewing the option data package to be delivered by Assembly Bio following completion of the Phase 1b studies.
• ABI-1179, another long-acting HSV helicase-primase inhibitor candidate, was contributed by Gilead under this collaboration.

Stakeholder Impact

• Shareholders: Positive clinical trial results could lead to increased investor confidence and potential share price appreciation due to reduced development risk and increased market potential.
• Patients (with recurrent genital herpes): Potential for a new, more effective, and more convenient treatment option (once-weekly/monthly dosing) that could significantly reduce outbreaks, viral transmission risk, and improve quality of life, addressing a long-standing unmet medical need.
• Employees: Positive progress in the clinical pipeline could enhance job security and morale.
• Gilead Sciences, Inc. (Collaborator): Positive results increase the likelihood of Gilead exercising its option for an exclusive license, potentially leading to future revenue streams for Assembly Bio and a valuable asset for Gilead.

Next Steps

• Move directly into Phase 2 clinical study preparation for ABI-5366.
• Initiate longer-duration Phase 2 clinical studies for ABI-5366 in mid-2026.
• Complete the ongoing Phase 1b study, which includes an ongoing cohort evaluating a monthly oral dosing regimen.
• Share interim data from the ABI-1179 study and the ongoing ABI-5366 Phase 1b monthly dosing cohort in the fall of 2025.
• Deliver the option data package to Gilead Sciences, Inc. following completion of the Phase 1b studies for Gilead to consider opting into an exclusive license for further development and commercialization of the helicase-primase inhibitor program.
• Submit data from the trial for presentation at future scientific meetings.

Key Dates

Recommendation

The interim Phase 1b results for ABI-5366 are exceptionally strong, significantly exceeding efficacy targets for HSV-2 shedding and genital lesion reduction, coupled with a favorable safety profile and convenient dosing potential. Given the substantial unmet medical need in recurrent genital herpes, with no new drugs approved in over 25 years, these results position ABI-5366 as a potential breakthrough therapy. The clear path to Phase 2 and the existing collaboration with Gilead Sciences further de-risk the program and highlight its commercial potential. This positive clinical data represents a major value inflection point for Assembly Biosciences, making it a compelling 'strong buy' for investors.

Keywords

Biotechnology, Pharmaceuticals, Clinical Trials, Herpes Simplex Virus, HSV-2, Genital Herpes, Antiviral, Helicase-Primase Inhibitor, ABI-5366, Drug Development, Phase 1b, Infectious Diseases